Leave Yourself Room

Ratio Therapeutics

Ratio Therapeutics has closed a $70M Series C, pushing company-reported total capital past $240M. The headline is the money, but the real story is what that capital has to carry: a clinical trial, another asset advancing toward the clinic, a broader oncology pipeline, and manufacturing capacity built for the realities of radiopharmaceutical development.

In radiopharma, the molecule is only part of the job. Isotopes decay, supply chains punish sloppiness, and a promising therapy still depends on manufacturing, logistics, and clinical execution lining up. Capital becomes infrastructure long before it becomes revenue.

Ratio is putting the round behind ATLAS, its Phase 1/2 study of [Ac-225]RTX-2358 in patients with relapsed or refractory soft tissue sarcoma. The FAP-targeted candidate uses actinium-225, and the trial is recruiting. Ratio also plans to move a next-generation radioligand candidate into the clinic and expand discovery across additional oncology targets.

Duquesne Family Office and Bristol Myers Squibb returned, while Catalio Capital Management, Eli Lilly and Company, and Wasatch Group joined as new investors. No lead investor was disclosed. Pretending every syndicate needs a star is how funding coverage turns into fan fiction.

Founded by Jack Hoppin and John Babich, Ratio has built around two platforms. Trillium is designed to optimize pharmacokinetics, including clearance and target affinity. Macropa provides chelation technology for therapeutic and imaging isotopes. The ambition is simple to describe and difficult to execute: deliver more radiation to a tumor and less to healthy tissue.

The leadership team includes Jack Hoppin, Chairman and CEO; John Babich, President and CSO; Matthias Friebe, CTO; and Colin Hayward, CMO. Partnered programs with Novartis, Lantheus, and Merck provide external validation without changing the central question: can Ratio's internal pipeline produce meaningful clinical data?

That is where this Series C earns its name. It is financing trial execution, another planned clinical entry, discovery expansion, platform development, and manufacturing scale at the same time. In radiopharma, those are not separate workstreams. They are one operating system.

The investors are underwriting two tests at once: can Ratio's engineered radiopharmaceuticals perform in patients, and can the company manufacture them reliably for later-stage development? Science without supply is a paper. Supply without evidence is a warehouse. That is the harder equation for investors.

The $70M is the headline. The more important measure now is how effectively Ratio converts that capital into clinical progress.

Orbital Sentry

Orbital Sentry has closed an undisclosed pre-seed round led by Ridgeline, with Superorganism and Hustle Fund participating. The capital will support initial sensor development and early commercial and government partnerships. That sounds like a financing update. It is also a bet that "real time" should mean something more useful than waiting for the next satellite to pass overhead.

Orbital Sentry is developing a persistent infrared imaging platform for geosynchronous orbit. A satellite in GEO can maintain a continuous view of the same region instead of delivering periodic snapshots. The company's first planned platform, Fire Sentry, is designed to detect wildfire ignitions within seconds and track changing heat signatures. When minutes can separate containment from catastrophe, latency is not a technical footnote. It is the product.

The same sensor thesis extends well beyond wildfire. Orbital Sentry is positioning persistent overhead infrared for missile launch warning, battlespace awareness, industrial monitoring, severe weather, and critical infrastructure. In any of those settings, a stale image can become an expensive form of nostalgia. That dual-use profile helps explain the investor mix.

Ridgeline brings an industrial and defense perspective. Superorganism invests across biodiversity, climate, and remote sensing. Hustle Fund specializes in the pre-seed stage. Together, they are backing a wildfire wedge with a broader sensing capability underneath it.

The company reports letters of intent across the insurance and utility markets. A Synthetic Data Program planned for this fall will allow organizations to test Fire Sentry-representative data before launch, giving prospective customers something tangible while the hardware moves through a longer development cycle.

Co-founder and CEO Mark Keremedjiev brings experience across space systems, infrared imaging, geospatial analysis, and Planet's Tanager-1 mission. Co-founder and CBO Elizabeth Foughty provides the commercial counterweight, with experience spanning NASA, RMS, CAPE Analytics, and Planet Labs. Deep tech needs both halves. A brilliant sensor without a market is a science project. A market story without a working sensor is a deck.

The financing amount was not disclosed. Orbital Sentry now has to turn a compelling GEO thesis into sensor progress, credible partner engagements, and evidence that persistent infrared data can fit the decision systems used by first responders, utilities, insurers, and defense customers.

The financing may be pre-seed, but the technical and commercial challenge is considerably larger. The next proof points will come from hardware execution, customer validation, and demonstrating that continuous infrared monitoring can become operational infrastructure rather than another promising space concept.

Base Power Company

Base Power Company just raised $1B in Series D financing at a $13B post-money valuation. That is a serious amount of capital for a company founded in 2023, but the sharper story is what arrived alongside the term sheet: Base Core, a 39.2 kWh home battery now rolling off the line at Factory 1 in Austin.

Base Power is not asking homeowners to become amateur energy traders. The company designs, builds, installs, owns, and maintains the battery, then uses that fleet to support the grid when demand spikes. When the grid goes down, the same hardware becomes whole-home backup.

That sounds simple until the operating model starts asking harder questions. Can Base manufacture at scale, send licensed crews into thousands of homes, manage energy-market exposure, and coordinate a virtual power plant without creating a very expensive science project?

Zach Dell, CEO and co-founder, and Justin Lopas, COO and co-founder, have built their answer around vertical integration. Base says its fleet now exceeds 500 MWh, its utility partnerships represent more than 200 MW of capacity, and Factory 1 is producing thousands of systems per month. Core comes in 39.2 kWh and 78.4 kWh configurations, with up to 36 or 72 hours of backup under reduced usage.

The round was led by Ribbit Capital, Addition, Valor Equity Partners, and JPMorganChase's Strategic Investment Group. The broader syndicate includes new and returning investors, including Altimeter, Coatue, Thrive Capital, Andreessen Horowitz, Lightspeed, and others.

The business lesson is not the capital itself. It is coordination. Base is combining manufacturing, installation, energy retail, grid services, software, and maintenance into a single operating system.

The timing helps. Electricity demand is climbing, centralized capacity is slow to build, and grid operators need flexible resources closer to load. A battery installed behind an existing residential interconnection can add useful capacity without waiting for every traditional infrastructure process to catch up.

That does not make execution cheap or easy. A $13B valuation comes with expectations that will not fit inside a press release, and hardware discipline has a way of collecting its bill in public. Base has now raised more than $2.5B in total capital to expand nationally, deploy Core in more homes, and hire the people needed to make the model travel.

The next test is bigger than selling batteries. It is whether a distributed network of homes can become meaningful grid infrastructure before demand outruns the system built to serve it.

Balance Theory

Balance Theory just raised $19M in Series A financing, led by SYN Ventures with returning support from DataTribe and TEDCO. The sharper signal is what investors believe deserves software now: cybersecurity's budget, vendor, renewal, and strategy layer.

Security teams run incidents with clear ownership, live data, and established operating procedures. Ask why they renewed one tool, cut another, or paid a premium for a third, and the answer may be buried in a spreadsheet, an inbox, or somebody's memory. The attackers are automated. Purchasing still runs on calendar reminders.

Balance Theory is building for that gap. Its AI-native platform connects three systems enterprises often assemble by hand: a system of record for persistent program context, intelligence built on proprietary cybersecurity market data, and execution that turns decisions into action through agents, skills, and workflows.

Security spending is not a set of isolated transactions. Every renewal changes leverage. A new product can close a control gap or create overlap. Every decision carries history that disappears when its owner leaves. Balance Theory wants to preserve that context before the next check gets signed.

The company says it manages more than $1B in cybersecurity investment spend, with average first-year customer ROI above 300%. Its materials reference more than 5,000 security vendors, 20,000 products, and average transaction savings above 18%. Those are company-reported figures, and they help explain why this round is about execution, not another dashboard with excellent posture and no pulse.

Co-founders Greg Baker, Lisa Mathias, and Nathan Necaise previously built Decision Lab, which Optiv acquired in 2017. Greg Baker remains CEO. The financing also brings Dan Burns, founder of Accuvant and former Optiv CEO, into the Executive Chairman role. That is a useful mix of founder continuity, channel history, and operator scar tissue.

SYN Ventures led the round alongside returning investors DataTribe and TEDCO, which backed Balance Theory's $3M seed round in 2022. The capital will support go-to-market execution, deeper integrations, expanded market intelligence, continued agent and skill development, and education around a different model for cybersecurity investments.

The financing raises a broader question for CISOs: can the budget layer remain administrative residue while threats, tools, and pricing move at machine speed? If every dollar has to defend the business, each investment decision should carry the same discipline as the incident it is meant to prevent.

Buzz Solutions

Buzz Solutions raised $5M in a Series A growth round built around a blunt reality: the electric grid is producing more visual data than utility teams can manually turn into decisions. Buzz called it growth funding, while Blackhorn Ventures described it as a Series A. GoPoint Ventures led the round, with Blackhorn Ventures and MaC Venture Capital participating, bringing reported total funding to $10.7M.

Kaitlyn Albertoli and Vikhyat Chaudhry founded Buzz Solutions in 2017 after meeting at Stanford University. Kaitlyn Albertoli serves as CEO, and Vikhyat Chaudhry serves as CTO. Their bet was not that utilities needed more images. It was that utilities needed a faster way to understand what those images were saying.

PowerAI analyzes imagery collected by drones, helicopters, fixed-wing aircraft, and ground teams, then turns it into asset inventories, condition assessments, and prioritized maintenance findings. PowerGUARD adds continuous substation monitoring through fixed RGB and thermal cameras for security, safety, and equipment-condition events.

Collecting inspection data is getting easier. Converting images into work orders and defensible operating decisions is where the labor hides. Buzz Solutions integrates visual intelligence with GIS, asset-management, and utility workflow systems instead of creating another island of software.

The $5M will support geographic expansion, new critical-infrastructure use cases, and broader product adoption. Buzz Solutions later reported 50% growth in its U.S. customer base, 100% year-over-year revenue growth, 40% team growth, and 110% partnership growth during 2024. Those are company-reported figures, and they show the thesis moving beyond a demo.

New York Power Authority, Southern California Edison, Dominion Energy, and AEP Texas appear across company and investor materials, alongside relationships with Esri, Skydio, and NVIDIA. HearstLab later backed Buzz Solutions and reported 90% defect-detection accuracy and a 70% reduction in analysis time across cited deployments.

U.S. Energy Information Administration expects data-center electricity consumption to keep climbing, while Federal Energy Regulatory Commission planning reforms push utilities toward more deliberate system investment. More load, more assets, more imagery, and less time for manual review make visual intelligence an operating requirement.

Buzz Solutions now has to prove its AI can survive utility procurement cycles, field conditions, legacy systems, and the consequences of being wrong. The question is how quickly utilities can convert data into action before the grid sends the bill.

Claryx

Claryx just came out of stealth with $3.5M in pre-seed funding and a pitch hospitals cannot afford to dismiss: find the outbreak before the outbreak finds the next patient.

Outlander VC led the round, with Company Ventures, Boost VC, Neon, Mana Ventures, 640 Oxford, and Precursor joining. The money matters, but the problem matters more. On any given day, about one in 38 U.S. hospital patients has at least one healthcare-associated infection. Hospitals pay in lives, bed capacity, penalties, and margins thin enough to make a spreadsheet sweat.

Brothers Kurt Hackenberger and Dirk Hackenberger built Claryx around a painfully specific memory. In 2004, their grandmother entered a hospital for a routine procedure, contracted C. difficile, developed sepsis, and spent three months there. Their family never learned where the infection came from. That question remains brutally hard for many hospitals to answer.

Claryx calls its platform the hospital immune system. It sequences patient infections and matches them with other cases and samples from air, sinks, wastewater, surfaces, and equipment. CloneLink connects those signals at the strain level, while AeroScan monitors the air. Infection-prevention teams can see what is spreading, where it may be coming from, and whether an intervention worked.

The economics turn strong science into a fundable company. Claryx says chemistry developed during Dirk Hackenberger's doctoral work cuts the most expensive sequencing step by more than 20x. Making genomic surveillance affordable enough to run continuously is where the business begins.

There is evidence behind the approach, but precision matters. A two-year University of Pittsburgh study at UPMC Presbyterian found 172 otherwise undetected outbreaks across 476 patients. Among the transmission routes traced and acted on, 96% went no further. Those are results from the published surveillance program, not disclosed Claryx outcomes.

Kurt Hackenberger brings the capital-allocation perspective from The Carlyle Group. Dirk Hackenberger brings infectious-disease genomics and antimicrobial-resistance research. One learned to price risk. The other learned to read it in DNA. Together, they want to make transmission visible early enough to change the outcome.

The financing gives Claryx the opportunity to prove that genomic intelligence can become routine hospital infrastructure instead of a specialist capability deployed after the damage is already visible. That is the real test for Kurt Hackenberger, Dirk Hackenberger, the Claryx team, and the investors backing the company.

Pie

Pie just added Amex Ventures to its cap table, and the interesting part is not a disclosed check size. There is not one. The interesting part is why the corporate venture arm of American Express sees leverage in a company built to help Main Street businesses turn digital discovery into measurable demand.

This follows Pie's June emergence from stealth and its $19.5M Series A led by Lightspeed Venture Partners, which brought disclosed funding to $23.7M at the time. The new investment amount and terms from Amex Ventures remain undisclosed, so the story is strategy, not arithmetic.

Pie is building an AI-powered growth platform around three products. AI Search improves visibility as discovery shifts into AI tools. Growth acquires customers across Google Maps, Yelp, and Nextdoor, while Front Desk answers calls, takes bookings, and responds to customer questions.

Small businesses rarely need another dashboard asking for attention. They need the phone to ring and marketing spend to connect to revenue. Pie reports reaching thousands of businesses while in stealth, driving more than 100,000 calls, and seeing many customers achieve 15% to 20% year-over-year sales growth.

Distribution is where the model gets sharper. Pie embeds its growth capabilities into vertical software platforms that already serve merchants. Its MoeGo partnership places Pie inside software used by more than 10,000 pet-care businesses, and MoeGo says participants generated an average 15x return on ad spend during the first few weeks.

For Amex Ventures, the fit is clear. Its commerce thesis includes technology that improves discovery, engagement, and conversion. Pie sits at that intersection, giving local operators AI measured by calls, bookings, and revenue instead of the interface in a demo.

Syed Ali and Akhil Mantripragada founded Pie in 2025 after meeting on Toast's New Ventures team. Now, as CEO and CTO, they are bringing that operator experience to a market software companies love to praise but routinely make too complicated to serve.

Margaret Lim, Managing Director at Amex Ventures, described Pie as a way to pair sophisticated AI-powered customer acquisition with an easy-to-use experience. That is the wager in plain English: give small businesses enterprise-grade growth machinery without handing them an enterprise-grade headache. That is where capital becomes useful.

The addition of Amex Ventures reinforces the broader signal behind Pie's strategy. AI earns a place in a small-business budget when it creates customers, answers demand, and proves what happened next.

Zao Asian Grill

Zao Asian Grill (Zao Asian Cafe) just brought Savory Fund to the table. This is a story about a 23-location Mountain West restaurant brand deciding its regional momentum is ready for a bigger operating system.

The pan-Asian fast-casual concept was founded by veteran restaurateur Dave Duffin and built around a simple promise: bowls, salads, wraps, tacos, and soup that move quickly without treating flavor like a scheduling conflict. Zao has expanded across Utah, Colorado, and Idaho, giving the model real-world repetition before the next growth push.

Restaurant growth is a physical business. Every new unit needs real estate, construction, hiring, training, supply discipline, and people who can deliver the same experience during a Tuesday lunch rush that the founders imagined on paper. Capital opens a door, but operating discipline keeps the kitchen from turning into expensive theater.

Zao enters the partnership with numbers that make the case more interesting. The company reported 18.2% same-store sales growth, driven by demand for cleaner eating, a growing catering business, and a steady cadence of limited-time offers. It also secured a separate $12.5M debt facility with Columbia Bank to accelerate new-location development, including a company projection of more than 10 openings through 2027.

Savory Fund's investment terms were not disclosed, so the loudest number is not the check size. The signal is the fit. Savory pairs capital with the operating machinery needed to turn emerging concepts into durable multi-unit brands. That is the part of the deal operators should watch.

Zao is the fourth investment in Savory Fund III, joining South Block, Bonrue Bakery, and Hawkers Asian Street Food. That portfolio context matters. Savory is not making a broad bet on restaurants as a category. It is building a collection of founder-led concepts with evidence of repeat demand, clear menus, and room to travel.

Tom Hartman, CEO, now has Savory's operating bench behind a foundation the company says has never been stronger. Paul Killpack adds deep restaurant finance experience after spending 13 years as CFO of Cafe Zupas, where the business grew from nine locations to more than 80. Founder Dave Duffin keeps the founding perspective in the room, which is exactly where it belongs when scale starts moving faster than memory.

The partnership gives Zao additional operating support for its next stage of expansion. The sharper question belongs to every operator watching from the next booth: when growth arrives, have you built a brand that can travel, or only a restaurant people happen to love where it already sits?

Obsidian Security

Obsidian Security just raised $85M in Series D funding at a $1.1B post-money valuation, and the real story is not another cybersecurity unicorn. It is the bill arriving for years of SaaS sprawl, now accelerated by AI agents that can touch the same applications, permissions, and data companies never fully mapped in the first place.

Crescent Cove Advisors led the round. Axios named Greylock and Menlo Ventures among the participating investors, while Obsidian Security says all existing investors backed the financing. That is less a victory lap than a vote that the security perimeter has moved again, this time into the trust relationships between people, software, and agents.

Obsidian Security was founded in 2017 by Ben Johnson, Glenn Chisholm, and Matt Wolff around a practical idea: business-critical data had moved into SaaS, but security teams could not see the identities, privileges, configurations, and integrations holding that environment together. The old perimeter had been outsourced across hundreds of applications.

Now AI agents are inheriting those same permissions. An agent does not arrive as a blank slate. It steps into years of accumulated access, stale accounts, OAuth connections, and configuration drift. Automation gets faster, but so does the blast radius when trust is wrong.

Obsidian Security says its platform covers more than 200 enterprise applications and connectors. It has expanded from SaaS posture management and threat detection into AI agent visibility, governance, and runtime security. A recent Claude Compliance API integration points to the direction of travel: monitor configuration risk before sensitive data takes a field trip.

The company reports adoption across 10 of the top 12 financial services firms, two of the top three telecommunications carriers, and three of the top five healthcare providers. Those are company-reported metrics, but the signal is hard to miss. This is a category being forced into existence by the way enterprises actually work.

Hasan Imam, CEO, Xinran Wang, CTO, and Chief AI Officer Matt Wolff now have fresh capital to scale that control layer. The Series D follows a $90M Series C in 2022. Based on the company's prior disclosed total, financing has now reached at least $204.5M.

The financing reinforces a broader shift in enterprise security. AI adoption is not just a model-selection problem. It is an identity, permission, and third-party application problem wearing a smarter interface. Companies that map trust before they automate it will move faster because they know where the floor is.

HappyRobot

HappyRobot just raised $150M in Series C funding, reached a $1.2B post-money valuation, and made a broader argument about where enterprise AI is headed: away from clever demos and into the work companies cannot afford to get wrong.

Prysm Capital led the round, Eurazeo co-led, and Andreessen Horowitz, Base10 Partners, and Y Combinator returned. KDT, Kfund, Orange, T.Capital, Bankinter, Endeavor Catalyst, and Wave-X also participated, bringing total funding to around $200M.

That investor syndicate is not betting on another chatbot with a nicer landing page. HappyRobot deploys AI agents into operational workflows across voice, email, chat, and SMS, then gives enterprises the context, governance, deterministic logic, and interfaces needed to keep those agents useful after the demo ends.

The company started in logistics, where small mistakes become expensive quickly. Now it is expanding into utilities, airlines, finance, insurance, manufacturing, retail, and telecommunications, all industries where coordination still lives inside phone calls, inboxes, documents, and systems that politely refuse to speak to one another.

HappyRobot reports more than 150 enterprise customers, including DHL, Kuehne+Nagel, Naturgy, Repsol, and Uber. The company says it has grown 5x since its $44M Series B, while its agents execute millions of tasks each month.

Initial agents typically go live within four to 12 weeks. HappyRobot reports more than 70% autonomous resolution, a 10x increase in operational capacity, and one customer automating 28,000 hours of work each month.

Those are company-reported metrics, but the shape of the business is clear. Enterprise AI does not win because the model can answer one more question. It wins when the system can act, preserve context, handle exceptions, and improve without forcing employees to rebuild their day around it.

Pablo Palafox, CEO, frames the destination as enterprise superintelligence: people and agents learning from the same operating context. Javi Palafox, COO, brings the operational perspective, while Luis Paarup, CTO, is building the infrastructure underneath it.

The new capital will expand HappyRobot's AI capabilities, enterprise integrations, deployment infrastructure, and global engineering, deployment, and go-to-market teams. The opportunity is enormous, but so is the burden of proving the platform can carry its logistics discipline into every new vertical.

The financing reflects a larger bet on enterprise automation. The companies that win may not be the ones with the most capable models, but the ones that can consistently do the work, learn the business, and make operational complexity disappear.

Yellow Card

Yellow Card's $40M Series B was announced on September 19, 2022, but the strategy it financed looks much clearer today. Polychain Capital led the round, joined by Valar Ventures, Third Prime, Sozo Ventures, Castle Island Ventures, Fabric Ventures, and others.

At the time, Yellow Card was known as a Pan-African cryptocurrency exchange. The company said the Series B brought its total funding to $57M after a $15M Series A in 2021. The capital was earmarked for African expansion, new products, and strategic partnerships.

Yellow Card launched in Nigeria in 2019. By the Series B, it reported more than 1M customers across 16 African countries. Chris Maurice and Justin Poiroux had built digital-asset access in markets where moving money across borders could feel like paying a toll every 10 feet.

Then the customer signal got louder. Businesses were not showing up for speculation. They needed hard-currency liquidity, treasury tools, supplier payments, and settlement rails that did not lose a week inside the plumbing.

Yellow Card followed the work. It shifted toward B2B stablecoin infrastructure, raised a $33M Series C in 2024, and discontinued its retail app by January 2026 to focus on institutional products for payments and treasury management.

That progression is what makes the $40M round worth revisiting. Funding announcements freeze a company at the ceremony: amount, investors, quote, applause. Operators should pay closer attention to what the capital allows the company to become after everybody leaves the room.

For Yellow Card, the answer became less "crypto exchange" and more payment infrastructure. Stablecoins became the rail. The underlying problem remained stubbornly analog: fragmented currencies, expensive correspondent banking, limited dollar access, and companies waiting for money that was technically already theirs.

The market is real, and so are the trade-offs. Chainalysis estimated stablecoins accounted for about 43% of Sub-Saharan Africa's crypto transaction volume from July 2023 through June 2024. The International Monetary Fund has pointed to lower payment friction alongside regulatory and monetary risks.

Chris Maurice, CEO, and Justin Poiroux, CTO, are building regulated connections between stablecoins and local payment systems, market by market. Yellow Card's 2026 expansion into supervised operations in Switzerland shows compliance is not paperwork sitting beside the product. It is part of the product.

The evolution of Yellow Card offers a useful lesson for founders. Capital creates opportunity, but its greatest value often comes from buying the time to listen more closely, narrow the customer, and rebuild around the problem people are actually willing to pay to solve.

Maximum

Maximum just launched with a $30M seed round led by CRV and one ambition: rebuild the operating system underneath modern banking.

Not another dashboard sitting on top of yesterday's infrastructure. Maximum is pitching an AI-native system spanning core banking and adjacent bank operations, with agents designed to automate work inside the bank instead of merely summarizing it.

Founder Randy Fernando knows this neighborhood. Fernando built Vault, acquired by Acorns, and Power Finance, acquired by Marqeta. Maximum is the third bank-focused company in that sequence, representing a bigger bet on the layer underneath it.

Maximum describes real-time visibility, continuous monitoring, predictive reasoning, custom bank agents, and a migration engine built around intelligent data extraction, compliance continuity, and automated reconciliation. Fernando told American Banker about an agent that checks OFAC data against daily transactions, identifies a potential match, and sends a recommendation to a human compliance officer.

Seconds instead of hours sounds attractive, but the human in the loop is the important part. In banking, speed without explainability is simply a faster route to a very expensive meeting.

The market is both frustrated and stubborn. American Banker reports that 76% of the 679 banks surveyed by the American Bankers Association used Fiserv, Jack Henry, or FIS, while 68% had stayed with their core provider for at least 10 years. The American Bankers Association also found that 69% were likely to remain with their provider at renewal, even as satisfaction remained soft.

That is Maximum's opportunity and its burden. Banks want better systems, but changing the system of record is closer to organ surgery than a software upgrade. The winner needs migration discipline, clean data, auditability, deterministic controls, regulatory credibility, and measurable operating gains.

Maximum's website also identifies Pear VC, Restive, Plug and Play Ventures, and Anthemis as backers. With no disclosed valuation or customer metrics, the company is still being judged on founder credibility, architecture, and execution.

Maximum is a fitting name because the company chose the hard version of fintech: compete beneath the apps, inside the bank, where every idea must survive a regulator, a migration plan, and a balance sheet.

The $30M gives Maximum room to prove that AI-native banking infrastructure can become dependable institutional machinery. The real test is whether banks trust it enough to replace systems they have spent decades building around.

CND Life Sciences

CND Life Sciences just closed $6.32M in debt financing, and the structure matters almost as much as the number.

An amended Form D filed with the U.S. Securities and Exchange Commission on August 3 shows the Scottsdale neurodiagnostics company sold the full offering to 14 accredited investors. The first sale occurred June 9. The filing does not identify the investors, interest rate, maturity, valuation, or use of proceeds. Private-market headlines often arrive before the footnotes.

What is visible is the business underneath the capital. CND Life Sciences was founded in 2017 by Todd D. Levine, MD, Christopher H. Gibbons, MD, MMSc, and Roy Freeman, MD, to pull more diagnostic information from a place medicine had largely overlooked: the skin.

Its Syn-One Test uses three small skin-biopsy samples to detect and quantify phosphorylated alpha-synuclein in cutaneous nerves. The protein is associated with Parkinson disease, dementia with Lewy bodies, multiple system atrophy, and other synucleinopathies. A 2024 JAMA study detected the marker in more than 92% of participants across four clinically confirmed disease groups, while the researchers called for additional validation in unselected populations.

That nuance is not a weakness. It is what serious diagnostics looks like when evidence must survive contact with clinicians, payers, regulators, and patients, not merely a pitch deck.

CND reported completing its 50,000th commercial Syn-One Test in November 2025. Its CLIA-certified, CAP-accredited laboratory also supports biopharma trials and quantitative applications through its AI-assisted NerValence platform.

The financing follows a $13.5M Series A announced in May 2025 and a separate $3M National Institutes of Health grant awarded that October. Equity, debt, and non-dilutive research funding are different tools, but together they reveal a company advancing scientific validation, clinical utility, reimbursement, commercial reach, and trial infrastructure.

Richard J. Morello, CEO, is responsible for turning that foundation into scale. Todd D. Levine serves as CMO, Christopher H. Gibbons as CSO, and Roy Freeman as Senior Scientific Advisor. The team now has to expand access without outrunning what the data can honestly support.

The financing reinforces a broader reality in neurodiagnostics. The question is not whether the market needs better tools for neurodegenerative disease. It is how quickly evidence-backed diagnostics can move from specialist adoption toward a broader standard of care, and what disciplined capital can do to close that distance.

Isengard Industries

Isengard Industries has closed a pre-seed round. The funding amount and valuation remain undisclosed.

Isengard is building AI-guided precision munitions and counter-drone systems for allied nations, with a production model designed around volume, distributed assembly, and sovereign control. The business is about ensuring the factory matters as much as the weapon.

That distinction is the story. Modern drone warfare keeps delivering the same blunt lesson: capability that cannot be produced at speed eventually becomes a brochure.

Isengard says its portfolio spans six systems, from short-range anti-tank munitions to an unmanned combat aircraft. The company reports that several systems are operational in Ukraine, its autonomy stack supports visual navigation and AI targeting in GNSS-denied environments, and its production design targets 3,000 systems per month. Those are company-reported claims, not independently verified performance guarantees.

The pre-seed backing comes from Y Combinator, Serra-de Estrela Investments Ltd, Backswing Ventures, Sterling Road, and A3 Management Group. This is private capital moving toward production architecture, not just another clever airframe.

Francisco Serra-Martins, CEO and co-founder, brings experience from Terminal Autonomy and the Australian Defence Force. James Tennant, CIO and co-founder, brings military service alongside private equity and private credit experience. Isengard has not disclosed the identities of its CTO or manufacturing co-founder.

The timing is not subtle. NATO announced more than $40B in planned allied investment in counter-drone capabilities over the next five years. Its Innovation Scale-Up Package also calls for private capital and manufacturing capacity to help nontraditional defense suppliers reach production scale.

That is the market Isengard is entering: governments want affordable autonomous capability, operators want systems that survive jamming, and allied nations want production they can own. The hard part is connecting performance, supply chains, local manufacturing, procurement, and repeatable output.

The round gives Isengard room to prove its production thesis can move from a sharp website to sustained delivery. If it can turn combat feedback into manufacturable systems and place production close to allied demand, it will be selling something bigger than a fleet. It will be selling industrial tempo.

The financing is only the opening chapter. The real measure will be whether Isengard can translate manufacturing ambition into reliable output when demand moves from pilot programs to sustained procurement.

Mariana Minerals

Mariana Minerals raised a $310M Series B to make mining move less like a century-old industry and more like the infrastructure race it has become.

Khosla Ventures led the round, with continued support from Andreessen Horowitz and Breakthrough Energy Ventures. Greenoaks, Halo Fund, Pax Ventures, StepStone Group, BHP Ventures, Washington Harbour Partners, Greycroft, General Innovation Capital Partners, Mitsubishi Corporation, In-Q-Tel, and Earthshot Ventures also joined. Mariana says total parent and project capital now stands at approximately $400M.

That distinction matters. Mariana develops, builds, and operates mines and refineries. Its software has to survive contact with ore bodies, equipment, construction schedules, chemistry, and the occasional rude awakening from physics.

MarianaOS is the operating layer. CapitalProjectOS connects engineering, procurement, scheduling, and cost control. MineOS links geological models, mine plans, fleets, and telemetry. PlantOS uses sensing, digital process models, and reinforcement learning for refining. Mariana says all three are in use across Copper One and Lithium One.

Mariana claims CapitalProjectOS can cut deployment time and cost in half. It says Copper One compressed a multi-year acquisition, permitting, and restart timeline into months, while Lithium One is on track for a designed-for-autonomy refinery less than three years after Mariana was founded.

Turner Caldwell, CEO and co-founder, started Mariana in 2024 after nearly a decade at Tesla. Juan Lozano, CTO, scaled machine learning systems at Affirm and Kite. Baker Tilney, CFO, previously built an integrated energy company that was later acquired by Vitol.

The Series B follows a 2025 Series A led by Andreessen Horowitz, with support from Breakthrough Energy Ventures and Khosla Ventures. That round brought total capital to $85M. One year later, the challenge is substantially larger.

The investor logic is straightforward. AI infrastructure, electrification, grid expansion, aerospace, and defense all require more critical minerals. Software becomes valuable when mines restart, refineries ramp, costs fall, and metal ships.

That is the wager behind $310M: not whether AI can write a mining memo, but whether it can help a vertically integrated operator build, mine, and refine with greater speed and less waste.

Mariana Minerals, Turner Caldwell, Juan Lozano, Baker Tilney, and the broader team now have the capital to test that thesis. The financing is substantial. The next chapter is wonderfully unforgiving: turning a bold systems vision into repeatable industrial output.

Function Health

Function Health's Series B financing has crossed the $450M mark, and the number is only half the story.

The company officially announced a $298M Series B in November 2025, led by Redpoint Ventures at a $2.5B valuation. Forge now reports two additional Series B tranches dated July 30, 2026, worth $94.11M and $65.08M. That brings the combined Series B financing to approximately $457.19M, with the latest investors undisclosed and the reported valuation increasing to $2.94B.

This is not a newly announced standalone $450M round. It is a financing story that kept getting larger because Function is trying to turn preventive health from an expensive scavenger hunt into a repeatable consumer product.

Function gives members access to more than 160 lab tests, longitudinal health tracking, clinician-reviewed insights, and optional MRI and CT imaging. The first-year membership costs $365, and the company says it now operates through more than 2,000 U.S. lab locations and has delivered more than 75 million results to members.

Healthcare usually waits for the smoke alarm. Function is selling people the wiring diagram, the sensors, and a record of what changed before the room fills up.

Jonathan Swerdlin, co-founder and CEO, has framed the mission around helping people live 100 healthy years. Mark Hyman, M.D., co-founder and Chief Medical Officer, anchors the clinical vision. Ziad Sultan, Chief Product and Technology Officer and former Spotify personalization executive, is responsible for making an enormous volume of health information feel less like homework and more like a product people can actually use.

The acquisition of Ezra added advanced imaging. The 2026 acquisition of Getlabs expanded mobile specimen collection. Medical Intelligence is designed to connect labs, imaging, wearables, medical records, and research into one continuously updated view.

That is where the investment thesis becomes more interesting. Investors are backing the possibility that longitudinal health data becomes a consumer platform, with testing, imaging, specimen collection, and intelligence operating as one integrated system.

Jonathan Swerdlin, Pranitha Patil, Mark Hyman, M.D., Seth Weisfeld, Dan Swerdlin, Ziad Sultan, and the broader Function Health team now have additional capital to test that vision. The latest financing provides more room to prove that proactive healthcare can scale without losing scientific discipline, privacy, or the human judgment that makes all that data useful.

The next test is the one money cannot grade: whether Function can turn broad access and enormous data volume into better decisions for ordinary people, not simply more measurements.